Michel J. Grothe, Spain

Unidad de Trastornos del Movimiento, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del RocíoCSIC/Universidad de Sevilla, Sevilla, Spain Unidad de Trastornos del Movimiento, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
Dr. Grothe is a senior researcher leading the Neuroimaging section of the Movement Disorders Group (Dr. Pablo Mir) at the Instituto de Biomedicina de Sevilla (IBiS), Spain. He also holds a co-affiliation as Senior Research Associate in the Molecular Neuroimaging Group (Schöll Lab) at the Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Sweden. Formally trained in physics and biology at the University of Cologne, he obtained a PhD in experimental psychiatry from Rostock University Medical Faculty, Germany, and completed his postdoctoral training at the German Center for Neurodegenerative Diseases (DZNE; Dr. Stefan Teipel). His research focuses on the use of multimodal neuroimaging techniques for studying neurodegenerative disease pathology in-vivo, and he has published over 100 peer-reviewed research articles in this field over the last 10 years. While most of his work evolved around neuroimaging and biomarker research in Alzheimer’s disease, he recently also became interested in using these in-vivo techniques to study the pathologic correlates of cognitive decline and dementia associated with Parkinson’s disease.

Presenter of 2 Presentations

DATA-DRIVEN IDENTIFICATION OF DISTINCT COGNITIVE SUBTYPES IN PARKINSON’S DISEASE DEMENTIA: ASSOCIATIONS WITH CLINICAL, GENETIC, AND BIOMARKER CHARACTERISTICS

Session Type
SYMPOSIUM
Date
12.03.2021, Friday
Session Time
12:00 - 14:00
Room
On Demand Symposia B
Lecture Time
12:15 - 12:30
Session Icon
On-Demand

Abstract

Aims

To conduct a data-driven exploration of distinct cognitive profiles among patients with Parkinson’s disease dementia (PDD), and characterize these cognitive subtypes with respect to clinical and genetic characteristics as well as biomarkers of Alzheimer’s disease (AD).

Methods

From the Parkinson’s Progression Markers Initiative (PPMI) cohort we identified all individuals with Parkinson’s disease and dementia (N=74). Of these, 51 (69%) were initially enrolled as de novo idiopathic PD and 23 (31%) had a confirmed LRRK2, GBA, or SNCA mutation. Ward’s hierarchical clustering was applied to domain-specific neuropsychological test data, and the derived PDD subgroups were then compared on clinical characteristics, prevalence of genetic mutations, as well as APOE4 genotype and CSF AD biomarkers (available for 44 and 59 patients, respectively).

Results

Clustering identified two distinct PDD subgroups with differing cognitive profiles (Fig. 1). Subgroups did not differ in overall dementia severity (MoCA: 19.7 vs 21.4, p=0.15) and were equally impaired in attention/executive functions, but Cluster-A (N=52, 70%) showed a more pronounced memory impairment, whereas Cluster-B (N=22, 30%) was more selectively impaired in visuospatial skills. Subgroups did not differ in duration or severity of motor symptoms, but Cluster-B trended towards an earlier age at PD onset (60.5 vs 65.3 years, p=0.07) and had a higher proportion of GBA mutation carriers (27% vs 4%, p=0.007). Subgroups did not differ in APOE4 prevalence or CSF amyloid-β or tau levels.

fig-1.jpg

Conclusions

We identified distinct memory-predominant and visuospatial-predominant dementia presentations among PDD patients. These distinct cognitive profiles do not appear to be driven by comorbid AD pathology.

Hide